Amgen’s CEO must go! - Recensione dipendente - Scientist presso Amgen

1,0
8 feb 2020
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Stock options, medical benefits and year end bonus.

Svantaggi

This once great company has been decimated and the staff demoralized by the greedy senior management which has wasted tens of billions of dollars on share buybacks to appease Wall Street and large shareholders. This money would have been better spent on more astute funding of research and superior scientific leaders. The main reason for the share buybacks is to maintain their EPS even though their revenues have been declining for the past few years. In addition, the decimation of the Cambridge site(Neuroscience, HTS, PKDM, Chemistry, and Toxicology) is an abomination and a perfect example of the treachery/greed/shortsightedness of the corrupt bourgeoisie of Thousand Oaks, CA.

Esplora altre recensioni su Amgen

5,0
29 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

benefits, pay, people, and work

Svantaggi

lots of work, stress, shift work

3,0
24 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Excellent compensation, benefits, and career development opportunities. Strong investment in innovation, patient-focused mission, and world-class manufacturing capabilities. The New Albany site offers exposure to complex biologics operations, large-scale capital projects, and opportunities to work alongside talented and dedicated professionals committed to delivering medicines to patients.

Svantaggi

The culture and leadership experience became increasingly inconsistent during the last year. Decision-making often lacked transparency, priorities shifted frequently, and employee feedback did not always appear to be valued. The people-centered culture that attracted many long-tenured employees seemed to drift, resulting in reduced trust, lower engagement, and increased organizational uncertainty.

Vedi recensioni per: Utile|Valutazione|Data|Tutto